This activity will explore how existing health care technology innovations can improve health equity for underserved patients and will examine the changing landscape of provider coverage and reimbursement. It will discuss anticipated solutions for vulnerable individuals (including Medicare and Medicaid dual-eligible individuals) and examine why certain telehealth programs have failed in the past. New approaches to benefit coverage for telehealth-related expenses will also be discussed, along with the future trends and essential elements associated with shifting to quality value-based care that can lead to improved patient satisfaction and outcomes, reduced health care costs and increased levels of health equity.

This activity will provide an overview of geriatric and frailty assessment tools that can assist in guiding cancer- and transplant-related decision making through the risk stratification of older individuals before therapy is initiated. Data surrounding the relationship among increased age, geriatric- and frailty-assessment results, and disease outcomes will also be explored. Key considerations in how to best incorporate these sometimes time-intensive assessments into practice will be outlined, along with discussion of how interprofessional collaboration among members of the health care team in the creation of care plans can facilitate quality care.

This activity will discuss these novel agents’ indications, risks, and benefits and will address which patient populations are most likely to benefit from particular agents. In addition, early-phase clinical trials and emerging therapies will be explored.

Lung cancer is the leading cause of cancer-related mortality in the United States. More than 80 percent of lung cancers are classified as non-small cell lung cancer (NSCLC). Immunotherapy has become integrated into the treatment of these patients, which has led to improvements in survival and quality of life.